Condition: Locally Advanced Gastric Adenocarcinoma · MSI-H/dMMR Gastric Cancer · MSI-H/dMMR Gastroesophageal-junction Cancer · Sponsor: Royal Marsden NHS Foundation Trust
A phase II study of peri-operative anti-PD1 (Zimberelimab) +/- anti-TIGIT (Domvanalimab) in resectable mismatch repair deficient (MMRd)/ high micro-satellite instability (MSI-H) gastric/gastro-oesophageal junctional (GOJ) adenocarcinoma (AC)
This description comes directly from the study's public registry record.
Project Manager · 02086613279 · ZODIAC@rmh.nhs.uk
Always discuss trial participation with your own doctor first.
| Addenbrooke's Hospital | Cambridge, Cambridgeshire, United Kingdom | Recruiting |
| Royal Devon University Healthcare Foundation Trust | Exeter, Devon, United Kingdom | Recruiting |
| Ninewells hospital and Medical School | Dundee, Dundee, United Kingdom | Recruiting |
| Kent & Canterbury Hospital | Canterbury, Kent, United Kingdom | Recruiting |
| Guy's and St Thomas' NHS Foundation Trust | London, London, United Kingdom | Recruiting |
| The Royal Marsden NHSFT | London, London, United Kingdom | Recruiting |
| St James's University hospital | Leeds, Yorkshire, United Kingdom | Recruiting |
| St Bartholomew's Hospital | London, United Kingdom | Recruiting |
| University College London Hospital NHS Foundation Trust | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06250036